Corium Shares Outstanding 2013-2018 | CORI

Current and historical number of shares outstanding for Corium (CORI) from 2013 to 2018. Diluted shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options.
Corium Annual Shares Outstanding
(Millions of US $)
2017 $29
2016 $22
2015 $19
2014 $10
2013 $2
2012 $2
2011 $0
Corium Quarterly Shares Outstanding
(Millions of US $)
Q3 2018 $36
Q2 2018 $36
Q1 2017 $36
Q4 2017 $29
Q3 2017 $31
Q2 2017 $26
Q1 2016 $22
Q4 2016 $22
Q3 2016 $22
Q2 2016 $22
Q1 2015 $22
Q4 2015 $19
Q3 2015 $18
Q2 2015 $18
Q1 2014 $18
Q4 2014 $10
Q3 2014 $18
Q2 2014 $6
Q1 2013 $2
Q4 2013 $2
Q3 2013 $2
Q2 2013 $2
Q1 2012 $2
Q4 2012 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.319B $0.032B
Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.621B 10.74
Teva Pharmaceutical Industries (TEVA) Israel $22.849B 6.38
Mylan (MYL) United Kingdom $19.499B 8.29
Bausch Health Cos (BHC) Canada $7.285B 5.44
Dr Reddy's Laboratories (RDY) India $5.340B 23.85
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.698B 4.59
Akorn (AKRX) United States $2.422B 11.99
Supernus Pharmaceuticals (SUPN) United States $2.258B 24.16
Assembly Biosciences (ASMB) United States $0.913B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.809B 116.67
CymaBay Therapeutics (CBAY) United States $0.706B 0.00
Homology Medicines (FIXX) United States $0.622B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.604B 0.00
Voyager Therapeutics (VYGR) United States $0.593B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.590B 0.00
Teligent (TLGT) United States $0.225B 0.00
Sol-Gel Technologies (SLGL) Israel $0.118B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.067B 0.00
Aevi Genomic Medicine (GNMX) United States $0.066B 0.00
Versartis (VSAR) United States $0.062B 0.00
Evoke Pharma (EVOK) United States $0.039B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.022B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00